← All trials
NCT04316065
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2020
- Primary completion
- Apr 20, 2020
- Completion date
- Apr 24, 2020
- First posted
- Mar 20, 2020
- Last posted
- May 26, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yuhan Pharmaceutical CompanyLead sponsor
- Metro HospitalCollaborator
- Metro HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.